Britain could face steep costs on its pharmaceutical exports to the United States after President Donald Trump unveiled his latest trade plan. According to Reuters, Trump announced a 100% tariff on pharmaceuticals imported into the U.S. unless companies establish a manufacturing presence within the country. The move is part of his broader effort to onshore drug production and cut reliance on foreign supply chains, a key theme of his trade and industrial policy.
While the European Union and Japan successfully negotiated trade agreements with Washington that capped pharmaceutical duties at 15%, the United Kingdom was not included in those exemptions. Britain was the first nation to sign a trade deal with Trump, but the pharmaceutical tariff rate remains unresolved in ongoing negotiations. This lack of finalization means UK-based pharmaceutical firms could be hit hard by the new policy.
Pharmaceutical imports from Britain accounted for approximately 3.3% of total U.S. pharmaceutical imports in 2024, based on U.S. trade data. Though that share is relatively small, the sector plays a critical role in bilateral trade and could face significant disruption if tariffs are implemented. Analysts suggest that higher costs may not only affect UK exporters but could also ripple through the American healthcare system, increasing prices for certain medicines and treatments.
Trump has framed this tariff strategy as essential to safeguarding U.S. economic security, boosting domestic manufacturing, and reducing vulnerabilities in global supply chains. However, critics warn the move could ignite new tensions with Britain and complicate future trade talks. The pharmaceutical industry, heavily dependent on global collaboration, may face difficult decisions about whether to expand operations in the United States or absorb the impact of rising tariffs.